

CONFLICT-OF-INTEREST STATEMENT

Name of Journal: World Journal of Hepatology

ESPS Manuscript NO: 13381

Natural interferon-beta treatment for patients with chronic hepatitis C in Japan

Reina Sasaki, Tatsuo Kanda, Shingo Nakamoto, Yuki Haga, Masato Nakamura, Shin Yasui, Xia Jiang, Shuang Wu, Makoto Arai, Osamu Yokosuka

Conflict-of-interest statement: Tatsuo Kanda reports receiving lecture fees from Chugai Pharmaceutical, MSD, Tanabe-Mitsubishi, Ajinomoto, Bristol-Myers Squibb, Daiichi-Sankyo, Janssen Pharmaceutical and GlaxoSmithKline; Makoto Arai reports receiving lecture fees from Chugai Pharmaceutical, Eisai, AstraZeneca, Daiichi Sankyo and Tsumura; Osamu Yokosuka reports receiving grant support from Chugai Pharmaceutical, Bayer, MSD, Daiichi-Sankyo, Tanabe-Mitsubishi, Bristol-Myers Squibb, Gilead Sciences and Taiho Pharmaceutical; the other authors have no conflict of interest statement.

Signature: Tatsuo Kanda **Date:** 1/15/2015